# Vyxeos® With Clofarabine for Pediatric AML

> **NCT07156435** · PHASE1 · RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 25 (estimated)

## Conditions studied

- Relapsed Pediatric AML
- Refractory Pediatric AML

## Interventions

- **DRUG:** Vyxeos 44 MG / 100 MG Liposome Injection
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT07156435
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07156435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07156435, "Vyxeos® With Clofarabine for Pediatric AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07156435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*